ADVANCES IN

Pharmacology and Chemotherapy

VOLUME 10

ADVANCES IN

Pharmacology and Chemotherapy

EDITED BY

Silvio Garattini

Istituto di Ricerche Farmacologiche "Mario Negri" Milano, Italy

F. Hawking

Clinical Research Centre Harrow, Middlesex, England

A. Goldin

National Cancer Institute Bethesda, Maryland

I. J. Kopin

National Institute of Mental Health Bethesda, Maryland TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC

Consulting Editor

R. J. Schnitzer

Mount Sinai School of Medicine New York, New York

VOLUME 10



ACADEMIC PRESS

New York and London

CORVERGIET C 1972, BY A

PERSON IN WRITING FROM

OR MECHANICAL, INCLUDING PROTOCORY SE

ADVANCES IN

Pharmacology and Chemotherapy

COPYRIGHT © 1972, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by ACADEMIC PRESS, INC. (LONDON) LTD. 24/28 Oval Road, London NW1

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 61-18298

PRINTED IN THE UNITED STATES OF AMERICA

CONTRIBUTORS TO THIS VOLUME

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- F. M. Berger (105), Wallace Laboratories, Division of Carter-Wallace, Inc., Cranbury, New Jersey
- John R. Egerton (381), Merck Institute for Therapeutic Research, Rahway, New Jersey
- Gerhard R. F. Krueger (1), Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Louis Lemberger (221), Lilly Laboratory for Clinical Research, Marion County General Hospital, and Departments of Pharmacology and Medicine, Indiana University School of Medicine, Indianapolis, Indiana
- WILLIAM O. McClure (185), Department of Biochemistry, University of Illinois, Urbana, Illinois
- S. J. Powell (91), Amoebiasis Research Unit, Institute for Parasitology, and Department of Medicine, University of Natal, Durban, South Africa
- Lowell O. Randall (119), Department of Pharmacology, Research Division, Hoffmann-La Roche Inc., Nutley, New Jersey
- William Schallek (119), Department of Pharmacology, Research Division, Hoffmann-La Roche Inc., Nutley, New Jersey
- Walter Schlosser (119), Department of Pharmacology, Research Division, Hoffmann-La Roche Inc., Nutley, New Jersey
- Federico Spreafico (257), Istituto di Ricerche Farmacologiche, "Mario Negri," Milano, Italy
- Manfred von Ardenne (339), Forschungsinstitut Manfred von Ardenne, Dresden-Weisser Hirsch, Deutsche Demokratische Republik



CONTENTS

CONTI	RIBUTORS TO THIS VOLUME	
	Morphology of Chemical Immunosuppression	
	GERHARD R. F. KRUEGER	
II. IV. V. VI. VII. VIII.	Introduction Molecular Biology and Morphology of Antibody Formation Types of Chemicals Used for Immunosuppression Pathophysiology of Chemical Immunosuppression Morphological Changes during Immunosuppression Pathological and Pathophysiological Synthesis Clinical Implications Comparative Pathology of Other Immunosuppressive Patterns Conclusions References	1 2 11 14 26 66 70 73 76 77
	Latest Developments in the Treatment of Amebiasis	
	S. J. Powell	
II.	Introduction	91 92 95 101 102
	Social Implications of Psychotropic Drugs	
	F. M. Berger	
II.	Introduction	105 106
V.	Patients Suicide and Antidepressants Potential for Social Damage Conclusions References	109 111 113 116 117
Rece	ent Developments in the Pharmacology of the Benzodiazep	ines
	WILLIAM SCHALLEK, WALTER SCHLOSSER, AND LOWELL O. RANDALL	
II.	Introduction	120 121 129

此为试读,需要完整PDF请访问: www.ertongbook.com

	Anticonvulsant Activity	132
V.	Behavioral Effects	137
VI.	Behavioral Effects	144
	Discussion of Neuropharmacology and Behavior	159
/III.	Metabolism	163
IX.	Biochemical Effects	174
X.	Discussion of Metabolism and Biochemistry	175
XI.	Future Developments	177
XII.	Conclusions	178
	References	179
	Effect of Drugs upon Axoplasmic Transport	
	가입니다. 그리고 있다. 다시 그리고 하고 있다는 경기에서 하는 것이 하는 것이 없는 것이 없는 것이 없는 것이 없는 것이 없는 것이 없다면 없다면 없다면 없다면 없다면 없다면 없다면 없다. 그리고 없는 것이 없다면	
	WILLIAM O. McClure	
8 I.	Introduction	185
II.	Introduction A General Consideration of Axoplasmic Transport	187
III.	Effect of Drugs upon Axoplasmic Transport	199
IV.	Conclusions	216
	References	216
	The Metabolism of the Tetrahydrocannabinols	
	A STATE OF THE PARTY OF THE PAR	
	Louis Lemberger	
	Introduction	221
	Nonenzymic Transformations of Cannabinoids	226
	In Vitro Metabolism of Tetrahydrocannabinols and an end of the control of the con	227
	In Vivo Studies with Δ^9 -Tetrahydrocannabinol	231
	Factors Affecting Δ^9 -Tetrahydrocannabinol Metabolism	241
VI.	Pharmacological Activity— Δ^9 -Tetrahydrocannabinol vs. an Active	
	Metabolite	244
VII.	Methods for Determining Δ ⁹ -Tetrahydrocannabinol or Its Metabolites in	
	Biological Fluids	247
VIII.	Biochemical Correlates of Clinical Findings	249
IX.	Concluding Remarks	251
	Concluding Remarks	251
	Riclogical Activities of Antihymphonetic Sorum	
	Biological Activities of Antilymphocytic Serum	
ar.	FEDERICO SPREAFICO	
	Introduction	257
II.	Production of Antilymphocytic Serum	259
III.	Characterization and Purification of Antilymphocytic Antibody	267
IV.	In Vitro Activities of Antilymphocytic Serum	272
V.	In Vivo Effects of Antilymphocytic Serum	276
VI.	Evaluation of Immunosuppressive Activity of Antilymphocytic Serum	303
	Mode of Action of Antilymphocytic Serum	307
VIII.	Clinical Uses of Antilymphocytic Serum	315
IX.	Complications of Antilymphocytic Serum Therapy	319
		324

Selective Multiphase Cancer Therapy: Conceptual Aspects and Experimental Basis

MANFRED VON ARDENNE

I. Introduction II. The Individual Phases—TIII. Conclusion References Addendum	The	ir S	Selection .	etiv	re M	lecl	hani	ism	ar	nd	Co	mb	ina	tion		1/1	339 340 377 377 380
The Application	n c	of .	An	the	elm	int	ics	in									
	J	ОН	R	. I	EGE	RTO	N										
I. Introduction	ing	DE.	oto	np)	H.	Ų.	1.2	ME			Z.	./		1	GR.	AU	381
II. Economic Losses	M			16	17	100	170	1.	Do.	115	18	1	OF	010	M	1	383
III. Preconditioning										65				1.4	1	18	384
IV. Anthelmintics in Feedlots																	385
References	wit.		O.Vo	130	503		11.1			2).	A.						391
AUTHOR INDEX	ond on t		1967	el	Set Set		11.00			n s			1.18			VI	393
SUBJECT INDEX	10	.35	100				(:)			at				0	14	ANI	422

CUMULATIVE TITLE INDEX . .

Morphology of Chemical Immunosuppression

GERHARD R. F. KRUEGER

Hematopathology Section, Laboratory of Pathology National Cancer Institute, National Institutes of Health Bethesda, Maryland

I.	Introduction	186	1
II.	Molecular Biology and Morphology of Antibody Formation		2
III.	Types of Chemicals Used for Immunosuppression		11
IV.	Pathophysiology of Chemical Immunosuppression	1114	14
	A. Hormones and "Antihormones"	g I	14
	B. Alkylating Agents . Holling Laven Language of Ground History Lo		15
	C. Antimetabolites		19
	D. Antibiotics		22
	E. CEnzymes, and to vacionation one veoloid aphysion	M	23
	F. Mitotic Inhibitors		24
	G. Polyanions	10.5	25
	H. Miscellaneous Substances		25
V.	Morphological Changes during Immunosuppression		26
	A. General Considerations	We	26
	B. Antibody-Forming Tissues 197	100	27
	C. Tissue Site of Antigen-Antibody Reactions	68	52
	D. Lesions Unrelated to Immune Reactions		62
VI.	Pathological and Pathophysiological Synthesis		66
VII.	Clinical Implications		70
	A. Transplantation C. D. W. H. S. B. D. B. M. M. T. S.	isc	70
	B. Autoimmune Diseases	Ų.	71
	C. Infectious Diseases.	i.	72
	D. Neoplastic Diseases		72
VIII.	Comparative Pathology of Other Immunosuppressive Patterns		73
	A. General Considerations	- PH	73
	B. Irradiation . 199 . (2319 la . s.f.) Thursday but sufficient	d.	73
	C. Antilymphocytic Sera		74
	D. Immunological Tolerance	191	74
	E. Immune Deficiency Syndromes		75
IX.	Conclusions		76
	References		77

to stimuse he base I still I. Introduction

In this chapter the author will try to correlate the results of three large fields of research, which, though originating at about the same time and

developing at about the same rate, have advanced in a parallel and independent fashion. Referred to are the fields of immunology and serology, pharmacology and chemotherapy, and pathology. If one reads present-day textbooks on immunology, pathology, or chemotherapy, the information gained is somewhat unilateral despite obvious effects of one field on one or both of the others. The only exception may be the fast-growing subspecialty of transplantation research.

No complete study of immunology, chemotherapy, or immunopathology is provided in this chapter; the reader may refer to the many already available review articles (Miescher and Müller-Eberhard, 1968; Letterer, 1967; Gell and Coombs, 1968; Diener, 1970; Steffen, 1968; Morrison, 1960; Sellei et al., 1970; Wilmans, 1964; Abramoff and LaVia, 1970; Mandel, 1959). Instead, the author will introduce a synthetic approach to the problem of immunosuppression and reintroduce at the same time the value of careful morphological investigations.

II. Molecular Biology and Morphology of Antibody Formation

Before concentrating on the main subject—the morphology of immunosuppression—a summarizing review needs to be given of the current knowledge on the normal immune response. Readers interested in detailed descriptions of this subject may refer to the "Biology of the Immune Response" by Abramoff and LaVia (1970), or for the morphology and pathology, to Letterer (1967), Cottier et al. (1969), and Turk (1970).

Violation of the integrity of the human or animal body by foreign substances of a certain nature is followed by a specific reaction of the injured body called an immune reaction. Foreign substances that are able to elicit an immune reaction are named antigens; if a known antigen in a given organism induces an immune reaction, this substance may be well called an immunogen; if it introduces tolerance, it may be called tolerogen. Both tolerance and immunity (i.e., allergy) can be caused by the same antigen at different dose levels, at different routes of administration, or at different ages of the recipient. The specific reaction of the affected individual toward the antigen is carried out by antibodies. Antibodies are proteins with a variable fraction of their molecule that, on induction, is synthesized in a way to fit specifically with a certain segment of the antigen. This antigenic segment is called the specific determinant. A few examples of various antigenic determinants are given in Table I, and an example of the composition of an antibody molecule is given in Fig. 1. The cellular and molecular events that are initiated by the entrance of an antigen into the living organism are summarized in Fig. 2.

TABLE I
Sizes of Various Antigenic Determinants

Antigen	Determinant	Size in most extended form (Å)	Molecular weight
Dextran	Isomaltohexaose	$34 \times 12 \times 7$	990
Silk fibroin	Gly [gly3ala3] tyr	27	632
	Dodecapeptide mixture	44	1000
G ₆₀ A ₄₀ , G ₆₀ A ₃₀ T ₁₀ and G ₄₂ L ₂₈ A ₃₀	Hexaglutamic acid	$36 \times 10 \times 6$	792
Polyalanyl bovine serum albumin	Pentaalanine	$25 \times 11 \times 6.5$	373
Polylysyl rabbit serum albumin	Penta- (or hexa-) lysine	$27 \times 17 \times 6.5$	659
Polylysyl phosphoryl bovine serum albumin	Pentalysine	$27 \times 17 \times 6.5$	659

From Kabat (1966), reprinted with the permission of the author and of Williams & Wilkins, Baltimore, Maryland.

Phagocytosis has been known since Metschnikoff (1892) as the first visible reaction of the host toward an administered antigen. Extensive studies of Nossal, Ada, and co-workers have shown that, in lymphoreticular tissues, antigenic materials are fixed by phagocytic sinus endothelial cells, by cortical and medullary histiocytes, and by dendritic reticulum cells of the follicle (Nossal et al., 1964; Ada et al., 1967; Lang and Ada, 1967; McDevitt, 1968). However, dendritic reticulum cells apparently do not phagocytize antigen but absorb it to their surface and so probably allow a close contact of antigenic determinant sites with immunoreactive lymphoid cells (Szakal and Hanna, 1968; Schoenberg et al., 1964). Antigen may persist 2-6 weeks in these various phagocytes and dendritic reticulum cells after a single primary injection. Within phagocytes, complex antigens then are broken down to simple antigenic molecules (Gill and Cole, 1965). This step of antigen processing appears important for the development of a primary immune response, although it may not be essential for all antigens (Pribnow and Silverman, 1967; Frei et al., 1965; Feldman and Gallily, 1967). From these phagocytes information for the synthesis of specific antibodies is passed to immunoreactive lymphoid cells via the transfer of ribonucleic acid (RNA) or RNA-antigen complexes (Pinchuck et al., 1968; Fishman and Adler, 1963a,b; Friedman et al., 1965; Askonas and Rhodes, 1965; Gottlieb et al., 1967). Since both ribonuclease (RNase) and pronase can destroy the activity of RNA extracted from sensitized animals,

Thr-Leu-Met.

Leu-Gly-Gly-Pro-Ser-Val-Phe-Leu-Phe-Pro-Pro-Lys-Pro-Lys-Asp-

Thr-Glu-(

Boy doubling reticulum cells of

Phe-Pro-Pro-Lys-Pro-Lys-Asp-Thr-Leu-Met-Leu-Leu-Gly-Gly-Pro-Ser-Val-Phe-Sammistered antigen. Extensive we shown that, in lympl ore neutra -x-& googene signs controlled cells. - Lys-Thr-Val-Ala-Prv -Lys-Val-Asp-Lys-Lys-Val-Glu-Pr -Lys-Val-Asp-Lys-Lys-Val-Glu-Pr

Example of the chemical composition of an antibody molecule (fragment). From Steiner and Porter (1967). Reprinted from permission of the copyright owner. Chemical Society. Reprinted by




Fig. 2. Biology of antibody formation.

a complex of RNA and of antigen or antigen fragments may be essential for the induction of antibody synthesis.

Morphologically, activation of phagocytes after administration of antigents is manifested by their increase in size and by the increase in number of cytoplasmic granules which parallel the rise in acid phosphatase and β -glucuronidase activity. These granules are recognized as lysosomes by electron microscopy, and, in addition, ribosomes, polyribosomes, and mitochondria are increased in number. The larger size and the metabolic activation of phagocytes renders these cells more prominent in lymphoreticular tissues.

Following antigen fixation and processing in phagocytes is the induction period, during which lymphoid cells synthesize *de novo* ribosomal RNA (rRNA) (Abramoff and LaVia, 1970). Histologically, activation (or transformation) of lymphoid cells to small basophilic reticulum cells (immunoblasts) with prominent pyroninophilia is noted in the primary follicle and in the paracortical region of lymphoid tissues. These cells aggregate to




Fig. 3. Paracortical region of a mouse lymph node draining the site of injection of tubercle bacteria in adjuvant. Note increased number of activated reticulum cells, (immunoblasts arrows). H&E; magnification ×375.




Fig. 4. Secondary follicle of a mouse lymph node draining the site of injection of bovine serum albumin. Note the division of the secondary follicle into the pale and the basophilic parts. H&E; magnification ×150.

form in the primary follicle a secondary follicle also called the germinal center (Figs. 3 and 4). This secondary follicle formation often is preceded by a transient dissociation of a preexistent secondary follicle (Congdon, 1962, 1964). Probably this dissociation is closely related to the period of induction, while reaggregation and de novo formation of secondary follicles represents the first step in antibody formation. Not in all cases of antigenic stimulation, however, is follicular dissociation obvious (Mariani et al., 1971; Congdon, 1969). By electron microscopy, activated lymphoid cells, i.e., small basophilic reticulum cells, show increased numbers of polyribosomes but only a little rough endoplasmic reticulum. Their nuclei are enlarged and contain prominent nucleoli. Some authors subclassify these cells according to their cytological details into basophilic stems cells, germinoblasts, and germinocytes (Lennert, 1961; Mori and Lennert, 1969), although these may only represent variant states of activity of the same type of cell. Histochemically, cells in the secondary follicle characteristically contain a high concentration in 5'-nucleotidase (Braunstein et al., 1958;

Lennert and Rinneberg, 1961), indicating that these cells are actively en-

gaged in nucleic acid metabolism.

Following the induction period is the period of actual antibody synthesis which follows the general biochemical pathways of protein synthesis (Kabat, 1968; Mahler and Cordes, 1968): transcription of information for protein synthesis from deoxyribonucleic acid (DNA) to RNA, and translation of this information from RNA into the basic polypeptide chain. Each cell capable of antibody synthesis contains the DNA-encoded information for protein synthesis, and, according to the clonal selection theory of Jerne (Jerne, 1955) and Burnet (Burnet, 1959), may even contain the information for a single specific antibody. Antigenic stimulation is interpreted as selection and activation of these cells to produce their precoded antibody congruent to the inducing antigen. Another older theory, the instruction theory of Breinl and Haurowitz (1930) and Haurowitz (1965), also may be still valuable. According to this theory, only the information for protein synthesis is DNA encoded. The antigenic determinant, probably attached to RNA, serves as a template to modify nonspecific transcription and impose the synthesis of the specific group in the antibody molecule.

Amino acids are assembled to immunoglobulin chains at the site of polyribosomes, directed and assisted by messenger RNA (mRNA) and transfer RNA (tRNA) (Mahler and Cordes, 1968; Williamson and Askonas, 1967). It appears possible that the size of polyribosomal units is directly related to the size of the immunoglobulin chain (Kuff and Roberts, 1967). As in the synthesis of other proteins, polyribosomes involved in immunoglobulin synthesis appear membrane-bound, i.e., they are a component of rough endoplasmic reticulum (DePetris and Karlsbad, 1965; LaVia et al., 1968). The release of antibody globulins from these membranes and from the cell is finally preceded by the addition of a carbohydrate

group (Melchers and Knopf, 1969; Swenson and Kern, 1968).

Histological changes in lymphoreticular tissues during the period of antibody synthesis consist of fully developed secondary follicles, various numbers of pyroninophilic reticulum cells in the paracortical region, and differentiation of lymphoid cells to plasma cells in the medullary cords of lymph nodes (Fig. 5) (Ringertz and Adamson, 1950; Movat and Fernando, 1965; Krüger, 1967b; Krüger and Harris, 1970; Harris and Harris, 1956; Congdon and Makinodan, 1961). Histochemically, markedly elevated activities of glucose-6-phosphate dehydrogenase and alkaline phosphatase are noted in basophilic reticulum cells (immunoblasts) (Turk, 1967). Basophilic reticulum cells contain abundant aggregated cytoplasmic ribosomes, and plasma cellular differentiation in the medullary cords is paralleled by the marked increase in rough endoplasmic reticulum. Accordingly, intra-




Fig. 5. Medullary cords of a mouse lymph node draining the injection site of bovine serum albumin. Note increased number in plasma cells. H&E; magnification ×675.

cellular antibody has been shown in basophilic reticulum cells of the secondary follicle (Pernis, 1967; Young and Friedman, 1967) and in cisternae lined by endoplasmic reticulum of plasma cells as well as their less well-differentiated precursors (DePetris and Karlsbad, 1965; Leduc et al., 1968; Avrameas and Lespinats, 1967; DePetris et al., 1963). Differentiation to antibody-producing cells usually is accompanied by cell proliferation in lymphoreticular tissues, the extent of which appears to depend upon the "strength" and on the dose of the antigen.

It is not yet well understood what the relationship is of the above-described mechanisms of antibody formation to the development of immune lymphocytes eliciting a cellular immune response. It appears that macrophages also play a role in cellular immunity (Dumonde, 1967) and that cell activation or transformation to pyroninophilic reticulum cells in the paracortical region of lymph nodes precedes the state of delayed hypersensitivity (Krüger and Harris, 1970; Oort and Turk, 1965). It has been suggested that immune lymphocytes may carry antibody-like substances

TABLE II

LIST OF IMMUNOSUPPRESSANTS AND CANCER CHEMOTHERAPEUTIC AGENTS

A. Hormones an	d antihormones
----------------	----------------

- 1. Corticosteroids
- 2. Corticosteroid antagonists (Metopirone, Mitotane)
- 3. Estrogens and progesterone

B. Alkylating agents

- 1. Nitrogen mustards
- 2. Ethyleneimines
- 3. Esters of alkylsulfonic acid
- 4. Epoxides

C. Antimetabolites

- 1. Pyrimidine and purine antagonists
- 2. Folic acid antagonists
- 3. Glutamine antagonists

D. Antibiotics

- 1. Chloramphenicol
- 2. Actinomycins
- 3. Mitomycin C
- 4. Daunomycin and adriamycin
- 5. Mithramycin
- 6. Bleomycin
- 7. Puromycin
- 8. Azotomycin
- 9. Neocarzinostatin
- 10. Streptonigrin

E. Enzymes and Child and the first had a new York and the soliton proposed

- 1. I-Asparaginase
- 2. Ribonuclease

F. Mitotic Inhibitors and the same of the

- 1. Colchicine and derivatives
 - 2. Podophyllin derivatives
 - 3. Vinca rosea alkaloids

G. Polyanions

- 1. Pyran copolymers
- 2. Polyinosinic acid-polycytidylic acid (poly I:C)

H. Miscellaneous Substances

- 1. Methylhydrazine derivatives
 - 2. Mycophenolic acid
 - 3. BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]

 Newer alkylating agents

此为试读.需要完整PDF请访问: www.ertongbook.com

4. Newer alkylating agents